DPP4 and COVID-19: The upregulation of DPP4 by glucocorticoids might contribute to the hyperglycemic effect of these steroid hormones but also could play a role in COVID-19 physiopathology, considering that glucocorticoids have been identified as potential COVID-19 therapeutic agents because of their targeted anti-inflammatory effects [134].